See more : ibis inc. (9343.T) Income Statement Analysis – Financial Results
Complete financial analysis of InterCure Ltd. (INCR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of InterCure Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- POONA DAL & OIL INDUSTRIES LTD (POONADAL.BO) Income Statement Analysis – Financial Results
- EarthLabs Inc. (SPOFF) Income Statement Analysis – Financial Results
- PepperLime Health Acquisition Corporation (PEPL) Income Statement Analysis – Financial Results
- China Fortune Land Development Co., Ltd. (600340.SS) Income Statement Analysis – Financial Results
- iomart Group plc (IOM.L) Income Statement Analysis – Financial Results
InterCure Ltd. (INCR)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.intercure.co
About InterCure Ltd.
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 355.55M | 388.68M | 219.68M | 65.04M | 8.93M | 0.00 | 0.00 | 0.00 | 1.40M | 5.65M | 8.25M | 8.47M | 12.07M | 13.23M |
| Cost of Revenue | 250.46M | 233.60M | 128.55M | 33.06M | 7.45M | 0.00 | 0.00 | 0.00 | 538.71K | 1.87M | 1.84M | 1.99M | 2.89M | 3.13M |
| Gross Profit | 105.10M | 155.08M | 91.13M | 31.98M | 1.48M | 0.00 | 0.00 | 0.00 | 862.71K | 3.78M | 6.41M | 6.47M | 9.18M | 10.10M |
| Gross Profit Ratio | 29.56% | 39.90% | 41.48% | 49.17% | 16.57% | 0.00% | 0.00% | 0.00% | 61.56% | 66.85% | 77.67% | 76.44% | 76.03% | 76.34% |
| Research & Development | 388.00K | 632.00K | 1.24M | 1.58M | 1.71M | 0.00 | 0.00 | 0.00 | 0.00 | 50.62K | 104.48K | 351.18K | 844.93K | 1.03M |
| General & Administrative | 64.30M | 91.72M | 30.73M | 17.86M | 76.36M | 9.81M | 1.12M | 1.40M | 2.02M | 3.17M | 2.88M | 4.52M | 5.16M | 8.59M |
| Selling & Marketing | 21.94M | 5.60M | 23.21M | 8.44M | 2.69M | 0.00 | 0.00 | 0.00 | 167.86K | 2.54M | 5.22M | 3.62M | 4.46M | 4.97M |
| SG&A | 86.24M | 97.32M | 53.94M | 26.30M | 79.05M | 9.81M | 1.12M | 1.40M | 2.19M | 5.71M | 8.10M | 8.14M | 9.63M | 13.56M |
| Other Expenses | 60.04M | 4.20M | 2.93M | 745.00K | 853.00K | 0.00 | 24.33K | 369.27K | 89.78K | 140.18K | 142.78K | 156.91K | 510.00K | 510.91K |
| Operating Expenses | 146.66M | 102.15M | 58.11M | 28.62M | 81.62M | 9.81M | 1.12M | 1.40M | 2.39M | 5.90M | 8.34M | 8.65M | 10.98M | 15.10M |
| Cost & Expenses | 397.12M | 335.76M | 186.65M | 61.68M | 89.06M | 9.81M | 1.12M | 1.40M | 2.92M | 7.77M | 10.19M | 10.64M | 13.87M | 18.23M |
| Interest Income | 4.55M | 844.00K | 130.00K | 21.00K | 141.00K | 0.00 | 0.00 | 0.00 | 19.52K | 0.00 | 0.00 | 3.74K | -68.51K | 3.55K |
| Interest Expense | 24.22M | 14.69M | 5.05M | 264.00K | 1.84M | 1.03M | 639.51K | 411.59K | 0.00 | 0.00 | 86.69K | 1.83M | 7.08M | 8.81M |
| Depreciation & Amortization | 13.17M | 11.70M | 7.39M | 3.25M | 23.00K | 10.00K | 4.00K | 979.00K | 870.52K | 23.36K | 142.78K | 112.08K | 224.55K | 496.72K |
| EBITDA | -23.90M | 64.50M | 37.45M | -34.53M | -21.20M | -10.12M | -1.09M | 0.00 | -1.64M | -3.77M | -1.88M | 45.38M | -1.65M | -4.60M |
| EBITDA Ratio | -6.72% | 16.59% | 17.11% | 2.78% | -237.55% | 0.00% | 0.00% | 0.00% | -116.99% | -39.08% | -22.79% | -25.10% | -13.65% | -34.76% |
| Operating Income | -41.57M | 52.80M | 28.19M | -1.45M | -80.14M | -10.62M | -3.98M | 1.20M | -2.51M | 2.67M | -1.94M | -2.17M | -1.80M | -5.00M |
| Operating Income Ratio | -11.69% | 13.58% | 12.83% | -2.23% | -897.78% | 0.00% | 0.00% | 0.00% | -179.11% | 47.28% | -23.47% | -25.67% | -14.95% | -37.82% |
| Total Other Income/Expenses | -19.72M | -6.79M | -9.45M | 92.00K | -3.15M | -2.18M | -1.28M | -938.57K | 627.79K | -1.12M | -4.67M | 45.62M | -4.96M | -7.51M |
| Income Before Tax | -61.29M | 43.84M | 18.74M | -38.31M | -3.67M | -12.80M | -5.26M | 265.42K | -1.88M | -3.79M | -6.61M | 43.44M | -6.76M | -12.52M |
| Income Before Tax Ratio | -17.24% | 11.28% | 8.53% | -58.90% | -41.10% | 0.00% | 0.00% | 0.00% | -133.98% | -67.13% | -80.08% | 512.92% | -56.01% | -94.64% |
| Income Tax Expense | 2.25M | 93.00K | 11.44M | -2.27M | -673.00K | -1.15M | 663.84K | 3.05M | -780.73K | 0.00 | 87.06K | 1.83M | 41.87K | 46.12K |
| Net Income | -61.96M | 44.82M | 7.30M | -36.04M | -3.00M | -12.80M | -5.26M | 265.42K | -1.88M | -3.79M | -6.61M | 43.44M | -6.80M | -12.56M |
| Net Income Ratio | -17.43% | 11.53% | 3.32% | -55.42% | -33.56% | 0.00% | 0.00% | 0.00% | -133.98% | -67.13% | -80.08% | 512.92% | -56.35% | -94.98% |
| EPS | -1.36 | 0.99 | 0.16 | -1.42 | -0.13 | -0.62 | -0.31 | 0.02 | -0.21 | -2.34 | -4.36 | 711.66 | -23.15 | -42.77 |
| EPS Diluted | -1.36 | 0.99 | 0.16 | -1.42 | -0.13 | -0.62 | -0.31 | 0.02 | -0.21 | -2.34 | -4.36 | 585.98 | -23.15 | -42.77 |
| Weighted Avg Shares Out | 45.56M | 45.35M | 46.92M | 25.40M | 23.30M | 20.60M | 16.78M | 12.58M | 8.85M | 1.62M | 1.51M | 380.97K | 293.74K | 293.74K |
| Weighted Avg Shares Out (Dil) | 45.57M | 45.35M | 46.92M | 25.40M | 23.30M | 20.60M | 17.11M | 12.90M | 8.85M | 1.62M | 1.51M | 462.21K | 293.74K | 293.74K |
Buy InterCure To Ride The Coming Wave Of Global Cannabis Growth
Legal cannabis around the world is just beginning but will surpass that of North America. Europe is one of the largest growth markets for companies in global cannabis.
InterCure: Highlighting A Profitable Israeli Cannabis Operator
InterCure is the leading cannabis operator in Israel. Israel is currently a medical market, with recreational legalization expected to occur over the coming years.
InterCure: A Leader In Global Cannabis
The global cannabis market will eventually be far bigger than North America. InterCure is a leading company in global pharmaceutical cannabis.
InterCure Ltd (INCR) CEO Alexander Rabinovitch on Q2 2022 Results - Earnings Call Transcript
InterCure Ltd (NASDAQ:INCR ) Q2 2022 Earnings Conference Call August 16, 2022 8:30 AM ET Company Participants Adam Haliva - Communications Officer Alexander Rabinovitch - CEO & Director Amos Cohen - CFO Conference Call Participants Victor Ma - Cowen and...
5 Cannabis Stocks You Don't Want to Hit 'Snooze' On
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will continue to develop in 2022.
Buying Into A Down Market (Podcast Transcript)
Ted Waller returns to discuss staying bullish but getting more realistic about the cannabis industry. Limited growth rates, margin compression and the need to keep our emotions out of investing.
InterCure Is Growing In The Massive Global Cannabis Market
Most of cannabis industry growth will occur outside North America. The road to global growth starts with medical cannabis.
The Holiday-Shortened Week Didn't Stop These 8 Cannabis Stocks
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will continue to develop in 2022.
Still A Lot More Work To Do In The Cannabis Industry (Podcast Transcript)
Michael Auerbach, Chairman of The Parent Company, updates us on the growth that hasn't shown up the way we expected. InterCure and the Israeli market.
What Happened With These 11 Cannabis Stocks This Week?
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will continue to develop in 2022.
Source: https://incomestatements.info
Category: Stock Reports